Biotechnology company Revvity has launched the Eonis Q system, a CE-IVD declared platform that helps laboratories conduct molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.
Immediate detection is critical for treatment of both conditions since for SMA there are disease modifying therapies that stop progression of disease, and for SCID, immunoglobulin treatments combined with stem cell therapies can potentially cure a child, if intervention comes in time. To date, however, molecular testing for these and other congenital disorders is relatively low, due in part to cost restrictions and the technical expertise required to perform and interpret these tests.
The Eonis Q system simplifies and streamlines molecular testing for both conditions using an innovative workflow that includes the Eonis Q96 instrument, the Eonis SCID-SMA kit and dedicated Eonis Easi software.
Turnaround time for the workflow from sample-in to result is approximately three hours. There are no required wash steps and fewer pipetting and centrifuging steps than other traditional methods. The Eonis Q system uses fewer consumables and one-time use plasticware than competitive systems thereby delivering cost efficiencies to labs.
Less waste and fast turnaround
Turnaround time for the Eonis Q workflow is approximately three hours, and the system exceeds industry standards in software capability, according to the company. There are no wash steps required and fewer pipetting and centrifuging steps than with other systems, further reducing workflow time. The system also uses fewer consumables and one-time use plasticware, helping to deliver further cost efficiencies for labs.
The compact size and smaller physical footprint of the system is ideal for all lab sizes, while offering additional benefits for low and medium-throughput labs, including those without a PCR clean room.
European standards for screening
The European Alliance for Newborn Screening in Spinal Muscular Atrophy (SMA), an advocacy group established by SMA Europe, mandates that by 2025 all newborns in Europe should be screened for SMA. The CE-IVD declaration of the Eonis Q system aims to work towards this goal.
The platform is smaller physically that other comparable systems and so is ideal for all lab sizes, it also offers additional benefits for low-and medium-throughput labs, including those without a PCR clean room.
Petra Furu, general manager of reproductive health at Revvity, said: “Molecular testing for inherited conditions like SMA and SCID will help children get a healthier start in life, and this aim is at the heart of our work.”
